Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

The Effects of Gabapentin in Treatment of Burning Mouth Syndrome: Retrospective Pilot Study

´ëÇѱ¸°­³»°úÇÐȸÁö 2014³â 39±Ç 3È£ p.96 ~ 99
ÇãÁØ¿µ, ¿Á¼ö¹Î, Á¤¼ºÈñ, ±è°æÈñ, ¾È¿ë¿ì,
¼Ò¼Ó »ó¼¼Á¤º¸
ÇãÁØ¿µ ( Heo Jun-Young ) - Pusan National University Dental Hospital Department of Oral Medicine
¿Á¼ö¹Î ( Ok Soo-Min ) - Pusan National University Dental Hospital Department of Oral Medicine
Á¤¼ºÈñ ( Jeong Sung-Hee ) - Pusan National University Dental Hospital Department of Oral Medicine
±è°æÈñ ( Kim Kyung-Hee ) - Inje University Busan Paik Hospital Department of Oral Medicine
¾È¿ë¿ì ( Ahn Yong-Woo ) - Pusan National University Dental Hospital Department of Oral Medicine

Abstract


Purpose: The objective of this retrospective pilot study was to evaluate the effectiveness of Gabapentin in patients with primary burning mouth syndrome (BMS).

Methods: Ten subjects were diagnosed with primary BMS (8 women and 2 men). The mean age was 60.1 years. They had clinical examination to exclude local factors such as the presence of Candida species, xerostomia, lichen planus, etc. They also underwent hematological examination to exclude secondary BMS due to systemic disorders. Pain was assessed by patients on an 11-point numerical rating score system (0 to 10). Gabapentin was administered at a starting dose of 300 mg/day, slowly titrated up to maximum of 1,800 mg/day. All patients were treated for 4 weeks.

Results: One half of the patients (n=5) obtained reduction in pain over the treatment period. Four patients reported no reduction in pain symptoms. One patient reported that symptoms were worsening. The average pain score before the treatment was 6.3 and after the treatment was 5.25. No significant relationship was detected between pretreatment and posttreatment pain score. Only one patient noted mild side effect (dizziness).

Conclusions: This retrospective pilot study provides no preliminary evidence that Gabapentin has effect in the management of BMS. However, further research (well-designed, randomized, and controlled trial with large sample) would be needed to investigate the efficacy of Gabapentin in treatment of BMS.

Å°¿öµå

Burning mouth syndrome; Gabapentin

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI